Search Results

You are looking at 1 - 7 of 7 items for :

Clear All
Open access

Maja Beus, Diana Fontinha, Jana Held, Zrinka Rajić, Miguel Prudêncio and Branka Zorc

REFERENCES 1. G. Padmanaban and P. N. Rangarajan, Heme metabolism of Plasmodium is a major antimalarial target, Biochem. Biophys. Res. Commun . 268 (2000) 665–668; 2. C. Even, S. Friedman and K. Lamouar, Bipolar disorder after mefloquine treatment, J. Psychiatry Neurosci . 26 (2001) 252–253. 3. F. de Pilla Varotti, A. C. C. Botelho, A. A. Andrade, R. C. de Paula, E. M. S. Fagundes, A. Valverde, L. M. U. Mayer, J. S. Mendonça, M. V. N. de Souza, N. Boechat and A. U. Krettli, Synthesis, antimalarial activity

Open access

Kanungnit Congpuong, Wittaya Saipomsud, Chutatip Chompoonuch, Paitoon Niemhom, Sumiti Vinayak and Wichai Satimai

References 1. Bureau of Vector Borne Disease. Malaria situation. Nonthaburi:Ministry of Public Health of Thailand, 2008. Available at 2. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A. In vivo sensitivity monitoring of mefloquine monotherapy and artesunatemefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006; 11: 211-9. 3. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim

Open access

Zlatko N. Kalvatchev and Iliya T. Tsekov


Progressive multifocal leukoencephalopathy (PML) is ademyelinating disease caused by infection with Polyomavirus hominis 2, popularly known as JC virus (JCV). The disease is usually fatal as it develops due to the progressive destruction of oligodendrocytes in multiple brain foci. Several substances that show effect against JCV have been investigated. However, only the antimalarial drug mefloquine has been reported to significantly influence the viral replication both in vitro and following in vivo therapy with good penetration and distribution of the drug at efficacious concentrations into the central nervous system (CNS). The current material presents some of the available published data, suggesting that the activity of mefloquine against JCV be considered for treatment of patients with PML.

Open access

Punit Shah, Rajashree Mashru, Yogesh Rane and Atul Badhan

surface methodology, AAPS PharmSciTech 8 (2007) article 27; DOI: 10.1208/pt0802027. P. P. Shah, R. C. Mashru, Y. M. Rane and A. R. Thakkar, Design and optimization of mefloquine hydrochloride microparticles for bitter taste masking, AAPS PharmSciTech 9 (2008) 377-389; DOI: 10.1208/s12249-008-9052-x. United States Pharmacopoeia XXIV, National Formulary XIX , USP Pharmacopoeilal Convention, Rockville 2000, pp. 1941-1943. Y. M. Rane, R. C. Mashru, M. G. Sankalia, V. B. Sutariya and P. P. Shah

Open access

Wiriya Rutvisuttinunt, Kurt E. Schaecher, Harald Noedl, Chan Thap Lon, Stuart Tyner, Charlotte A. Lanteri, Krisada Jongsakul, Delia Bethell, Bryan L. Smith, David L. Saunders and Mark M. Fukuda

one of 3 antimalarial regimens (artesunate monotherapy, artesunate–mefloquine–primaquine, or quinine–tetracycline), were collected from two clinical sites lying on either side of the Thai–Cambodian border: Tasanh, western Cambodia (2006-2007); and Trat, Thailand (2005-2006). The outcome of treatment was classified according to the WHO guidelines for the treatment of malaria. Study protocols were approved by relevant local (081 NECHR) and U.S. Army (HSRRB log No. A-13922; WRAIR Study Numbers 1296 and 1327) IRBs and written informed consent was obtained from all study

Open access

Quan Liang

., Tesana S., Dose-response relationships and tegumental surface alterations in Opisthorchis viverrini following treatment with mefloquine in vivo and in vitro, Parasitol Res., 2009, 105(1), 261-266. 10.1007/s00436-009-1395-z Keiser J. Odermatt P. Tesana S. Dose-response relationships and tegumental surface alterations in Opisthorchis viverrini following treatment with mefloquine in vivo and in vitro Parasitol Res. 2009 105 1 261 266 [17] Zhang X.L., Dong Y.X., Han S., Da R., Li Y.H., Shu J., et al., Study on liver injury and model of rat infected by Clonorchis

Open access

Supat Chamnanchanunt, Pravinwan Thungthong, Sirvicha Kudsood, Waraporn Somwong and Manassamon Hirunmassuwan

) treatment (6 days) and then artesunate (5 days) i.v. (5 days) + (N/A) (2 days) + primaquine (unknown) (2 days) mefloquine (14 days) Other antibiotic Ceftriaxone N/A Ceftriaxone, metronidazole Ceftriaxone Ceftriaxone Ceftriaxone NEG treatment gentamicin, piperacillin doxycycline ciprofloxacin Onset of AIHA (days 12th 1st 14th 9th 7th 11th 2nd after antimalarial treatment) Diagnostic method Hemoglobin